Table 3.
OHSS outcomes of high-risk treatment and control groups
| Treatment groups (n = 161) | Control group | ||||
|---|---|---|---|---|---|
| Letrozole group | Mifepristone group | GnRH-ant group | Three-drug group | ||
| (n = 43) | (n = 51) | (n = 39) | (n = 28) | (n = 120) | |
| Paracentesis (n) | 7 (16.3 %) | 9 (17.7 %) | 7 (17.9 %) | 4 (14.3 %) | 21 (19.2 %) |
| Length of hospital stay(days) | 7.0 ± 2.9 | 7.4 ± 2.5 | 7.1 ± 2.8 | 6.8 ± 2.1 | 7.3 ± 2.7 |
| Severity of OHSS | |||||
| Mild (n) | 24 (55.8 %) | 26 (51.0 %) | 19 (48.7 %) | 15 (53.6 %) | 65 (54.2 %) |
| Moderate (n) | 12 (27.9 %) | 15 (29.4 %) | 13 (33.3 %) | 8 (25.0 %) | 33 (27.5 %) |
| Severe (n) | 7 (16.3 %) | 10 (19.6 %) | 7 (18.0 %) | 5 (17.9 %) | 22 (18.3 %) |
| Complications (n) | 0 | 0 | 0 | 0 | 1b |
| Luteal phase(days)a | 10.9 ± 2.6 | 10.5 ± 1.9 | 10.7 ± 2.4 | 10.4 ± 2.3 | 11.2 ± 3.1 |
Values are means ± SD unless otherwise stated. Values in parentheses are percentages. OHSS ovarian hyperstimulation syndrome, NS not statistically significant
aLuteal phase = interval between oocyte retrieval and next menstrual cycle
bOne patient experienced ovarian torsion